Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 7Other hematologic neoplasm 5Thoracic 3Gynecologic 3Plasma cell 2Myeloid 2Genitourinary 2Gastrointestinal 2Other solid neoplasm 1Lymphoid 1CNS 1Breast 1

Conditions

Mesothelioma, Malignant 1

Interventions

Cisplatin 147pembrolizumab 129Carboplatin 126Injections 108Pemetrexed 99Paclitaxel 97Gemcitabine 85Irinotecan 75Cyclophosphamide 72Nivolumab 71Docetaxel 68Bevacizumab 59Oxaliplatin 50Fluorouracil 50Capecitabine 48atezolizumab 46Leucovorin 42Etoposide 42tislelizumab 40toripalimab 36fludarabine 32Drug Therapy 32Ipilimumab 30Topotecan 29durvalumab 28Vincristine 27Specimen Handling 27Early Intervention, Educational 27Radiotherapy 26Interviews as Topic 26

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Monatide (IMS 3015) × Other solid neoplasm × Clear all
NCT01265433 2024-10-09

Galinpepimut-S (WT-1 Analog Peptide) Vaccine in Malignant Pleural Mesothelioma After Combined Modality Therapy

Sellas Life Sciences Group

Phase 2 Completed
41 enrolled 12 charts
Other solid neoplasmThoracic

Mesothelioma, Malignant

Data powered by HemOnc (CC BY 4.0) Colophon âš¡